Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
Alexander Scheiter(University of Regensburg), Kirsten Utpatel(University of Regensburg), Anja M. Sedlmeier(University Hospital Regensburg), Hauke Christian Tews(University Hospital Regensburg), Felix Steger, Marco J. Schnabel(University of Regensburg), Elisabeth Bumes(University Hospital Regensburg), Kristina Wohlfart(University Hospital Regensburg), Konstantin Drexler(University Hospital Regensburg), B. Zwicker(University Hospital Regensburg), Florian Lüke(University Hospital Regensburg), Daniela Hirsch(OTH Regensburg), Till Kaltofen(University Hospital Regensburg), Alexander Immel(University Hospital Regensburg), Sabine Einhell(University of Regensburg), Ines Schönbuchner(University Hospital Regensburg), Wolfgang Dietmaier(University of Regensburg), Ulrich Kaiser(University of Applied Sciences Landshut), Christina Brummer(University Hospital Regensburg), Frederik Hierl(University of Regensburg), Monika Klinkhammer‐Schalke, Diego F. Calvisi(University of Regensburg), Sophie Schlosser-Hupf(University Hospital Regensburg), Matthias Grube(University of Regensburg), Davor Lessel(University Hospital Regensburg), S. A. Klemm(University of Regensburg), Ramona Erber(University of Regensburg), Arne Kandulski(University Hospital Regensburg), Felix Keil(University of Regensburg), Elena Lüftl(University of Regensburg), Tom Schneider(University of Regensburg), Elena Wutzlhofer(University of Regensburg), Simon Mellin(University of Regensburg), Stephan Seitz(University Hospital Regensburg), Markus Perl(University Hospital Regensburg), Tobias Pukrop, Julia Maurer, Johannes Meier, Sebastian Haferkamp(University Hospital Regensburg), Matthias Evert(University of Regensburg), Christian Schulz(University Hospital Regensburg), Daniel Heudobler(University of California San Diego), Margit Klier-Richter(University of Regensburg), Anja Troeger(University Hospital Regensburg)
Cited by 0
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
|Gastroenterology|2006|726